Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation.

Nurwidya F, Takahashi F, Takahashi K.

J Nat Sci Biol Med. 2016 Jul-Dec;7(2):119-23. doi: 10.4103/0976-9668.184695. Review.

3.

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.

He Y, Wang Y, Boyle T, Ren S, Chan D, Rivard C, Li X, Li J, Zhou C, Hirsch FR.

Med Sci Monit. 2016 Jan 26;22:276-83.

4.

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Plönes T, Engel-Riedel W, Stoelben E, Limmroth C, Schildgen O, Schildgen V.

J Pers Med. 2016 Jan 15;6(1). pii: E3. doi: 10.3390/jpm6010003. Review.

5.

Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study.

Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, Qin GY, Zhao NQ.

BMJ Open. 2015 Dec 23;5(12):e009419. doi: 10.1136/bmjopen-2015-009419.

6.
7.

Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis.

Kim HJ, Kang SH, Chung HW, Lee JS, Kim SJ, Yoo KH, Lee KY.

Thorac Cancer. 2015 Sep;6(5):629-35. doi: 10.1111/1759-7714.12234. Epub 2015 Feb 14.

8.

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.

Umelo IA, De Wever O, Kronenberger P, Van Deun J, Noor A, Singh K, Teugels E, Chen G, Bracke M, De Grève J.

Oncotarget. 2015 Aug 21;6(24):20132-44.

9.

Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients.

Romero-Ventosa EY, Blanco-Prieto S, González-Piñeiro AL, Rodríguez-Berrocal FJ, Piñeiro-Corrales G, Páez de la Cadena M.

Springerplus. 2015 Apr 9;4:171. doi: 10.1186/s40064-015-0891-0. eCollection 2015.

10.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.

Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR.

Oncoscience. 2014 Aug 7;1(8):522-8. eCollection 2014.

11.

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.

Fang S, Wang Z.

Drug Des Devel Ther. 2014 Sep 26;8:1595-611. doi: 10.2147/DDDT.S69690. eCollection 2014. Review.

12.

Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.

Liang W, Zhang Y, Kang S, Pan H, Shao W, Deng Q, Shi X, Wang W, He J.

J Thorac Dis. 2014 Sep;6(9):1239-50. doi: 10.3978/j.issn.2072-1439.2014.07.33.

13.

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.

Paz-Ares L, Soulières D, Moecks J, Bara I, Mok T, Klughammer B.

J Cell Mol Med. 2014 Aug;18(8):1519-39. doi: 10.1111/jcmm.12278. Epub 2014 Aug 6.

14.
15.

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer.

Yuan Y, Li XF, Chen JQ, Dong CX, Weng SS, Huang JJ.

Onco Targets Ther. 2014 May 28;7:841-52. doi: 10.2147/OTT.S34124. eCollection 2014. Review.

16.

Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.

Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, Otsuka H, Sato F, Ishida F, Kikuchi N, Hirota N, Sato K, Sano G, Sugino K, Sakamoto S, Takai Y, Shibuya K, Iyoda A, Homma S.

J Thorac Oncol. 2014 Apr;9(4):483-7. doi: 10.1097/JTO.0000000000000125.

17.

Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report.

Vitale MG, Riccardi F, Mocerino C, Barbato C, Monaco R, Galloro P, Gagliardi N, Cartenì G.

J Med Case Rep. 2014 Mar 24;8:102. doi: 10.1186/1752-1947-8-102.

18.

Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.

Ulivi P, Zoli W, Capelli L, Chiadini E, Calistri D, Amadori D.

Mol Clin Oncol. 2013 Jul;1(4):575-581. Epub 2013 Mar 29. Review.

19.

Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer.

Li H, Xie L, Lai RS.

Mol Clin Oncol. 2013 Jan;1(1):195-199. Epub 2012 Oct 15.

20.

In-depth analysis shows synergy between erlotinib and miR-34a.

Zhao J, Kelnar K, Bader AG.

PLoS One. 2014 Feb 14;9(2):e89105. doi: 10.1371/journal.pone.0089105. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk